Omics Data Generation Center (ODGC) for the Acute to Chronic Pain Signatures (A2CPS) Program - A2CPS Extension Administrative Supplement

项目总结 慢性疼痛是一个主要的健康问题，也是成年人寻求医疗服务的最常见原因之一[1]。它是 与生活质量降低、活动受限、抑郁和阿片类药物相关的实质性发病率 依赖性[2]。2016年，约有5000万美国成年人患有慢性疼痛，其中约 其中40%的人有高冲击性慢性疼痛[2]。慢性疼痛的社会成本估计为5600亿美元 每年的直接医疗费用、生产力损失和残疾计划[3]。生物机制 防止最初侮辱后急性疼痛的缓解，并推动从急性疼痛向慢性疼痛的过渡 很难理解[4，5]。缺乏经过严格验证的生物标志物来预测哪些患者 因此，易受从急性疼痛状态向慢性疼痛状态转变的影响是阻碍发展和 实施全人群和个性化的预防性疼痛干预措施[6]。这样做的主要目标是 项目是建立A2CPS Omics数据生成中心(ODGC)来生成基因组变异， 来自两个疼痛队列的代谢学、脂体学、蛋白质组和exRNA数据，每个队列由1800名受试者组成， 在急性疼痛发作后的基线、6周和3个月采集生物液样本。这些样品 将用于生成多组数据，以验证40个指示易感性或 对慢性疼痛发展的恢复力，以及确定新的候选生物标记物。

PROJECT SUMMARY Chronic pain is a major health concern and one of the most common reasons adults seek medical care [1]. It is associated with substantial morbidity linked to reduced quality of life, restricted mobility, depression, and opioid dependence [2]. In 2016, approximately 50 million U.S. adults were afflicted with chronic pain, with approximately 40% of them having high-impact chronic pain [2]. The societal cost of chronic pain is estimated at $560 billion annually in direct medical expenses, lost productivity, and disability programs [3]. The biological mechanisms that prevent the resolution of acute pain after the initial insult and drive the transition from acute to chronic pain are poorly understood [4,5]. The lack of rigorously validated biomarkers to predict which patients are more susceptible to the transition from acute to chronic pain states is thus a major gap hindering the development and implementation of population-wide and individualized preventive pain interventions [6]. The primary goal of this project is to establish the A2CPS Omics Data Generation Center (ODGC) to generate genomic variant, metabolomic, lipidomic, proteomic, and exRNA data from two pain cohorts consisting of 1800 subjects each, with biofluid samples collected at baseline, 6 weeks, and 3 months after an acute pain episode. These samples will be used to generate multi-omic data to validate 40 primary outcome biomarkers indicating susceptibility or resilience to development of chronic pain, as well as to identify new candidate biomarkers.